Breakthrough in Hyperpigmentation Treatment: MELAFLASH SET Protocol

Breakthrough in Hyperpigmentation Treatment: MELAFLASH SET Protocol

• 5th June 2026
• Thierry PIOLATTO

MELAFLASH SET’s clinical results that change the landscape

Recent advancements in dermatological science have brought to light the MELAFLASH SET protocol, which presents a promising strategy for addressing hyperpigmentation issues. This innovative approach is founded on robust pathophysiological principles and has undergone extensive clinical evaluation. New findings have emerged, confirming both the tolerability and effectiveness of this protocol.

MOVING BEYOND THE ANTI TYROSINASE APPROACH

The treatment of pigmentary disorders continues to pose significant challenges within aesthetic dermatology. Traditionally, tyrosinase inhibition has been the go-to method. However, this approach often falls short in tackling the inflammatory and vascular aspects associated with hyperpigmentation. DermEden's expertise shines through in this area, as the efficacy of their protocol has been validated by a clinical study supervised by dermatologists.

TRANEXAMIC ACID: A UNIQUE DEPIGMENTING ACTION

Central to this innovative treatment is Tranexamic Acid (TXA). Initially recognized for its role in coagulation, TXA has gained acceptance for its unique ability to inhibit the plasminogen pathway. This action reduces inflammatory and vascular mediators, as well as limits the transfer of melanosomes. When combined with Niacinamide, TXA effectively targets the inflammatory mediators that contribute to pigment rebound, making it highly effective for conditions such as melasma, post-inflammatory hyperpigmentation (PIH), and post-acne hyperpigmentation. Notably, TXA has been shown to be as effective as hydroquinone—the standard treatment—while avoiding its common drawbacks.

For more information: www.DERMEDEN.com

Previous Article

You May Also Like

Input your search keywords and press Enter.